MoonLake Immunotherapeutics (NASDAQ:MLTX) Cut to “Strong Sell” at Zacks Research

Zacks Research downgraded shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) from a hold rating to a strong sell rating in a research note published on Tuesday,Zacks.com reports.

A number of other equities analysts also recently commented on the stock. UBS Group set a $24.00 target price on shares of MoonLake Immunotherapeutics in a research note on Friday, January 9th. Oppenheimer reiterated an “outperform” rating and issued a $30.00 price target on shares of MoonLake Immunotherapeutics in a report on Thursday, November 6th. BTIG Research raised MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and set a $24.00 price objective on the stock in a research note on Friday, January 9th. Jefferies Financial Group lowered MoonLake Immunotherapeutics from a “buy” rating to a “hold” rating and set a $8.00 target price for the company. in a research report on Monday, September 29th. Finally, Wolfe Research cut MoonLake Immunotherapeutics from an “outperform” rating to an “underperform” rating in a report on Tuesday, September 30th. Seven analysts have rated the stock with a Buy rating, five have assigned a Hold rating and five have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $25.77.

MoonLake Immunotherapeutics Stock Performance

MLTX stock opened at $15.62 on Tuesday. MoonLake Immunotherapeutics has a twelve month low of $5.95 and a twelve month high of $62.75. The firm has a market cap of $1.00 billion, a price-to-earnings ratio of -4.70 and a beta of 1.21. The business’s fifty day simple moving average is $14.21 and its two-hundred day simple moving average is $29.68. The company has a quick ratio of 8.50, a current ratio of 8.50 and a debt-to-equity ratio of 0.25.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its earnings results on Wednesday, November 5th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.21). During the same quarter in the previous year, the firm earned ($0.56) EPS. Analysts predict that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Da Silva Jorge Santos sold 70,000 shares of the business’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $14.49, for a total value of $1,014,300.00. Following the completion of the transaction, the chief executive officer directly owned 2,878,577 shares of the company’s stock, valued at approximately $41,710,580.73. The trade was a 2.37% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Kristian Reich sold 72,908 shares of the company’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $14.43, for a total value of $1,052,062.44. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 402,908 shares of company stock valued at $5,987,162. 12.02% of the stock is owned by company insiders.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

A number of large investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC lifted its position in shares of MoonLake Immunotherapeutics by 24.9% during the fourth quarter. SG Americas Securities LLC now owns 21,888 shares of the company’s stock valued at $288,000 after buying an additional 4,362 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of MoonLake Immunotherapeutics by 342.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 174,161 shares of the company’s stock worth $1,249,000 after acquiring an additional 134,764 shares in the last quarter. FNY Investment Advisers LLC purchased a new stake in MoonLake Immunotherapeutics during the third quarter valued at approximately $28,000. Caitong International Asset Management Co. Ltd lifted its position in MoonLake Immunotherapeutics by 22,387.5% during the third quarter. Caitong International Asset Management Co. Ltd now owns 84,553 shares of the company’s stock valued at $606,000 after acquiring an additional 84,177 shares during the last quarter. Finally, Voleon Capital Management LP acquired a new stake in MoonLake Immunotherapeutics in the third quarter valued at approximately $289,000. 93.85% of the stock is currently owned by institutional investors.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunomodulatory therapies for autoimmune and inflammatory diseases. The company leverages a proprietary platform designed to selectively modulate key immune cell populations, aiming to restore immune balance and reduce tissue damage with targeted biologic candidates.

Its lead asset, MLTX101, is a recombinant immune cell modulator in clinical development for myositis, including inclusion body myositis and dermatomyositis.